Senti Biosciences Inc (SNTI)

Apr 28, 2025, 7:00 AM EDT - 1 day ago

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Apr 24, 2025, 8:35 AM EDT - 5 days ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Apr 21, 2025, 9:05 AM EDT - 8 days ago

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Apr 16, 2025, 9:15 AM EDT - 13 days ago

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Apr 10, 2025, 8:45 AM EDT - 19 days ago

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Apr 7, 2025, 8:45 AM EDT - 22 days ago

Senti Bio Joins Webull Corporate Connect Service Platform

Apr 3, 2025, 9:00 AM EDT - 26 days ago

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 5 weeks ago

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Mar 13, 2025, 4:01 PM EDT - 6 weeks ago

Senti Bio Appoints Feng Hsiung to Board of Directors

Feb 25, 2025, 8:00 AM EST - 2 months ago

Senti Bio Strengthens Leadership Team with Strategic Hires

Dec 16, 2024, 8:00 AM EST - 4 months ago

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Dec 3, 2024, 8:00 PM EST - 5 months ago

Senti Biosciences Announces New Employment Inducement Grants

Dec 2, 2024, 11:44 AM EST - 5 months ago

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Dec 2, 2024, 7:10 AM EST - 5 months ago

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Dec 2, 2024, 7:02 AM EST - 5 months ago

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Nov 14, 2024, 4:05 PM EST - 5 months ago

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Sep 3, 2024, 8:15 AM EDT - 8 months ago

Senti Bio to Participate in Upcoming Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 9 months ago

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Aug 5, 2024, 8:05 AM EDT - 9 months ago

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Jul 16, 2024, 8:30 AM EDT - 10 months ago

Senti Bio Announces Reverse Stock Split

Jul 1, 2024, 8:05 AM EDT - 10 months ago

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

May 13, 2024, 8:15 AM EDT - 1 year ago

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

May 9, 2024, 4:05 PM EDT - 1 year ago

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Apr 30, 2024, 8:05 AM EDT - 1 year ago

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

Jan 5, 2024, 4:05 PM EST - 1 year ago

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Dec 22, 2023, 6:30 AM EST - 1 year ago

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Nov 13, 2023, 4:15 PM EST - 1 year ago

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

Nov 12, 2023, 1:45 AM EST - 1 year ago

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

AZN BNTX BSX

Nov 6, 2023, 4:05 PM EST - 1 year ago

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

Oct 31, 2023, 9:06 AM EDT - 1 year ago

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Senti Bio to Participate in Upcoming Conferences

Aug 11, 2023, 8:35 AM EDT - 1 year ago

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

Aug 10, 2023, 8:35 AM EDT - 1 year ago

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

May 20, 2023, 8:05 AM EDT - 2 years ago

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 9, 2023, 4:05 PM EDT - 2 years ago

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 2, 2023, 4:45 PM EDT - 2 years ago

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting